High infusion parameters for pump-assisted and manual push 20% subcutaneous immunoglobulin (SCIg), or IgPro20, were well tolerated by patients with primary immunodeficiency disorder (PID), according to a recent abstract prepared for the American Academy of Allergy, Asthma & Immunology 2020 Annual Meeting.
High infusion parameters for pump-assisted and manual push 20% subcutaneous immunoglobulin (SCIg), or IgPro20, were well tolerated by patients with primary immunodeficiency disorder (PID), according to a recent abstract prepared for the American Academy of Allergy, Asthma & Immunology 2020 Annual Meeting.
Researchers evaluated treatment-emergent adverse events (TEAEs) for IgPro20. Sold under the name Hizentra, IgPro20 was first approved for the treatment of PID and is also approved for chronic inflammatory demyelinating polyneuropathy. The study (NCT03033745) assessed safety and tolerability of increasing infusion rates/volumes.
According to the Immune Deficiency Foundation, PID consists of more than 400 rare, chronic disorders in which part of the body’s immune system is missing or functions improperly as a result of hereditary or genetic defects.
In the open-label, nonrandomized phase 4 study, patients receiving IgPro20 were assigned to:
Assignments were based on prior experience with pump-assisted infusions at the highest approved IgPro20 parameters or frequent manual push infusions (~25 mL/h).
The rate of TEAEs per infusion was low across cohorts: 0.145, 0.228, and 0.085 in the pump-assisted volume cohort, the pump-assisted flow rate cohort, and the manual push flow rate cohort, respectively. There were no clinically meaningful differences in TEAE frequency, type, intensity, or duration among cohorts, and rates of TEAEs per infusion did not increase with increasing infusion parameters.
Most TEAEs were mild/moderate infusion site reactions (ISRs). There were causally related ISRs in 4 patients (26.7%) in the pump-assisted volume cohort (0.079/infusion); 1 patient discontinued due to mild injection site pain.
In the pump-assisted flow rate cohort, 8 patients (44.4%) had related ISRs (0.131/infusion); 1 patient (5.6%) reported 2 severe related ISRs, but none discontinued.
In the manual push flow rate cohort, 6 patients (37.5%) had related ISRs (0.043/infusion); 1 patient (6.3%) had a severe, unrelated serious TEAE (suicide attempt) leading to discontinuation.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More